DrugPatentWatch Database Preview

Drugs in Development Information for GWP42003-P

Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

What is the drug development status for GWP42003-P?

GWP42003-P is an investigational drug.

There have been 24 clinical trials for GWP42003-P. The most recent clinical trial was a Phase 3 trial, which was initiated on December 9^th 2019.

The most common disease conditions in clinical trials are Syndrome, Lennox Gastaut Syndrome, and Epilepsies, Myoclonic. The leading clinical trial sponsors are GW Research Ltd, University of Colorado, Denver, and Colorado Department of Public Health and Environment.

There are eight hundred and two US patents protecting this investigational drug and four international patents.

Summary for GWP42003-P

US Patents	802
International Patents	4,112
US Patent Applications	2,052
WIPO Patent Applications	1,314
Japanese Patent Applications	5
Clinical Trial Progress	Phase 3 (2019-12-09)
Vendors	23

Recent Clinical Trials for GWP42003-P

Title	Sponsor	Phase
An Open-label Extension Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome	GW Research Ltd	Phase 3
Investigation of Cognitive Outcomes With Cannabidiol Oral Solution	GW Research Ltd	Phase 4
Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome	GW Research Ltd	Phase 3

See all GWP42003-P clinical trials

Clinical Trial Summary for GWP42003-P

Top disease conditions for GWP42003-P

Top clinical trial sponsors for GWP42003-P

See all GWP42003-P clinical trials

US Patents for GWP42003-P

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
GWP42003-P		Pharmaceutical formulations	GW Pharma Limited (Cambridge, GB)
GWP42003-P		Compositions and methods for treating chronic inflammation and inflammatory diseases	Infirst Healthcare Limited (London, GB)
GWP42003-P		Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene diols	KANNALIFE SCIENCES, INC. (Huntington, NY)
GWP42003-P		METAP2 inhibitors and methods of treating obesity	SynDevRx, Inc. (Cambridge, MA)
GWP42003-P		Compositions, uses and methods for making them
GWP42003-P		Pre-spray emulsions and powders containing non-polar compounds	Virun, Inc. (Pomona, CA)

International Patents for GWP42003-P

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
GWP42003-P	Australia	2002231970	2021-02-14
GWP42003-P	Canada	2438097	2021-02-14
GWP42003-P	Canada	2533400	2021-02-14
GWP42003-P	China	1886117	2021-02-14
GWP42003-P	Cyprus	1115072	2021-02-14
GWP42003-P	Czech Republic	20032458	2021-02-14